FitLife Brands, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2022. The filing was signed October 14, 2022. Comparative 2021 amounts were restated for revenue-recognition errors.
Business context
FitLife Brands develops and sells nutritional supplements under NDS, iSatori, BioGenetic Laboratories, Energize, and other brands. Products are distributed primarily through GNC and more than 17,000 specialty, mass-market, and online retail locations. GNC represented 70% of first-quarter 2022 revenue, while online sales represented approximately 26%.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $7.455 million | $5.599 million | +33% |
| Gross profit | $3.272 million | $2.795 million | +17% |
| Gross margin | 43.9% | 49.9% | Down 6.0 percentage points |
| Operating income | $1.596 million | $1.261 million | +27% |
| Net income | $1.290 million | $1.405 million | Down 8% |
| Basic EPS | $0.28 | $0.33 | Down $0.05 |
| Diluted EPS | $0.26 | $0.30 | Down $0.04 |
| Adjusted EBITDA | $1.723 million | $1.424 million | +21% |
Operating margin was approximately 21.4% in Q1 2022 versus 22.5% in Q1 2021. Net margin was approximately 17.3% versus 25.1%, reflecting the absence of the $453,000 PPP loan-forgiveness gain recognized in the prior-year quarter.
Cash provided by operating activities was $1.134 million, compared with $289,000 in Q1 2021. No investing cash flows occurred. Financing activities provided $29,000 from stock-option exercises. Cash increased to $11.060 million from $9.897 million at December 31, 2021.
At March 31, 2022, working capital was approximately $15.377 million. Current assets were $20.009 million, including $11.060 million of cash, $1.689 million of accounts receivable, and $7.095 million of inventory. Total liabilities were $4.722 million, consisting primarily of current operating liabilities and lease liabilities. No borrowings were outstanding under the $2.5 million revolving line of credit. Total lease liabilities were $144,000.
Material changes versus the prior comparable period
- Revenue increased 33%, driven by growth in wholesale and online direct-to-consumer sales.
- Cost of goods sold increased 49%, causing gross margin to decline from 49.9% to 43.9%. Management attributed the margin decline primarily to delayed receipt of approximately $250,000 of supplier rebates.
- General and administrative expense increased 15% to $982,000, primarily because of $94,000 of additional external legal and consulting expenses related to special projects.
- Selling and marketing expense increased modestly to $680,000 due mainly to higher cooperative marketing expenses for a wholesale partner. Management expects this elevated level to continue.
- Operating income increased despite lower gross margin, but net income declined because Q1 2021 included the $453,000 PPP loan-forgiveness gain.
- Operating cash flow improved substantially, principally from working-capital management, although accounts receivable and inventory increased during the quarter.
- Shareholders’ equity increased to $18.772 million from $17.346 million at year-end 2021. Treasury shares were retired during the quarter, and 3,472 stock options were exercised.
Guidance, outlook, risks, and unusual items
- Management expects cash from operations, existing cash, and available revolver borrowings to fund liquidity for the next twelve months, but states that no assurance can be given.
- Management expects online revenue to continue increasing relative to prior periods and is focusing on higher-margin online sales.
- The Company has experienced inflation in product procurement and has generally offset it through customer price increases. Further inflation could pressure results if price increases cannot be passed through.
- COVID-19-related retail closures, supply-chain disruptions, manufacturing lead times, demand changes, and potential future restrictions could materially affect results. Management reported no goodwill impairment trigger during the quarter but identified worsening COVID-19 conditions as a potential future impairment risk.
- GNC concentration is significant: GNC represented 70% of Q1 2022 revenue and 75% of gross accounts receivable at March 31, 2022.
- The Company disclosed a material weakness in disclosure controls and internal control over financial reporting. The weakness contributed to historical revenue, cost of sales, accounts receivable, inventory, and tax errors requiring restatement of prior periods.
- The Company hired accounting consultants and a new CFO in August 2022 and is implementing a remediation plan, but stated that controls remained ineffective as of March 31, 2022.
- The Company filed Form 15 in July 2022 to deregister its common stock and terminate Exchange Act reporting obligations, but stated it intends to withdraw the filing after returning to current filer status.
- The Company reported no material litigation and no defaults on senior securities.
- The revolving credit facility’s maturity date was later extended to December 23, 2022; the filing states that other terms were unchanged.
Investor verification items
- Verify the scope and impact of the revenue-recognition restatement and the related 2021 comparative amounts.
- Monitor remediation of the disclosed material weaknesses and whether subsequent filings confirm effective internal controls.
- Assess dependence on GNC, including revenue, receivables, customer concentration, and any changes in GNC’s financial or operating condition.
- Determine whether gross-margin pressure from delayed supplier rebates, inflation, and marketing costs persists.
- Confirm the status and availability of the $2.5 million revolving credit facility and its December 23, 2022 maturity.
- Evaluate working-capital trends, particularly inventory growth, inventory-obsolescence allowances, receivable collections, and product-return reserves.
- Confirm the status of Form 15 and the Company’s ongoing SEC reporting obligations.